XM does not provide services to residents of the United States of America.
B
B

BBBiotech

News

BB Biotech Q3 Net Loss At CHF 157 Mln

BRIEF-BB Biotech Q3 Net Loss At CHF 157 Mln Oct 25 (Reuters) - BB BIOTECH AG BION.S : STRATEGIC REALLOCATION OF PORTFOLIO ASSETS PROGRESSING CLOSED Q3 WITH A NET LOSS OF CHF 157 MN POSITIVE RESULTS FROM A PHASE I/II STUDY OF ION582 (ANGELMAN SYNDROME) AT NINE-MONTH MARK, SHOWED NET PROFIT OF CHF 16 MN COMPARED TO A NET LOSS OF CHF 316 MN IN FIRST N
B

Swiss stocks - Factors to watch on October 25

Swiss stocks - Factors to watch on October 25 ZURICH/GDANSK, Oct 25 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Friday: UBS UBSG.S The incipient migration of clients from Credit Suisse to UBS should take about another 18 months, UBS CEO Sergio Ermotti said on Thursday. SIKA SIKA.S Swiss industrial and construction chemicals company Sika reported a 5.5% increase in sales for the first nine months of 2024 on Friday, and confirmed its outlook for the year.
B
S
S
U
S

BB Biotech Q2 Net Loss Of CHF 87 Mln

BRIEF-BB Biotech Q2 Net Loss Of CHF 87 Mln July 26 (Reuters) - BB BIOTECH AG BION.S : A NET LOSS OF CHF 87 MN WAS INCURRED IN Q2 COMPARED TO A NET LOSS OF CHF 13 MN IN PRIOR-YEAR PERIOD A NET PROFIT OF CHF 173 MN WAS GENERATED DURING FIRST HALF OF 2024 COMPARED TO A NET LOSS OF CHF 267 MN IN SAME PERIOD OF 2023 BB BIOTECH'S SHARES CLOSED PERIOD 12.0% LOWER IN CHF AND 11.3% LOWER IN EUR BOARD OF DIRECTORS HAS APPOINTED DR.
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.